clinical trial · NCT05687032
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Pfizer·phase4·completed·n = 44
Acute Lymphoblastic Leukemiainotuzumab ozogamicin
brief summary
This is an open-label, single-arm, multicenter study in Chinese patients with relapsed or refractory CD22-positive B-cell ALL. The objective of the study is to confirm the efficacy, safety, and PK of inotuzumab ozogamicin in patients with relapsed or refractory B-cell ALL from mainland China.
started
Feb 24, 2023
primary completion
Aug 7, 2024
completion
Nov 6, 2025
last updated
Dec 3, 2025
official title
A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF INOTUZUMAB OZOGAMICIN IN CHINESE ADULT PATIENTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol